<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="912">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05469360</url>
  </required_header>
  <id_info>
    <org_study_id>CNIO752B12201</org_study_id>
    <secondary_id>2022-000921-26</secondary_id>
    <nct_id>NCT05469360</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants</brief_title>
  <official_title>A Randomized, Participant and Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of a Single Intrathecally Administered Dose of NIO752 to Lower Cerebrospinal Fluid Total Tau Levels in Participants With Early Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of&#xD;
      NIO752 in patients with early Alzheimer's disease (AD)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1b, randomized, double-blind, placebo-controlled study, in which patients&#xD;
      with early AD will receive a single intrathecal dose of NIO752.&#xD;
&#xD;
      A total of 24 participants will be enrolled into one of two cohorts (each with 12&#xD;
      participants) and randomized into receiving one dose of NIO752 or placebo in 2:1 ratio.&#xD;
&#xD;
      Participants will remain in this study for a 170-day follow-up period including approximately&#xD;
      3 in-clinic visits.&#xD;
&#xD;
      Cohorts will be enrolled sequentially.&#xD;
&#xD;
      Study assessments will include pharmacokinetics (PK), physical and neurological examinations,&#xD;
      ECGs, vital signs, standard clinical laboratory evaluations (hematology, blood chemistry, and&#xD;
      urinalysis), CSF routine laboratory test, adverse event, and serious adverse event&#xD;
      monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 9, 2022</start_date>
  <completion_date type="Anticipated">November 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 22, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1b</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cerebrospinal total tau from baseline to Day 85</measure>
    <time_frame>Baseline, Day 85</time_frame>
    <description>Total tau protein levels in cerebrospinal fluid. More frequent timepoints might be added as deemed necessary per the site Investigator's judgment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and serious adverse events</measure>
    <time_frame>Baseline up to 170 days</time_frame>
    <description>Adverse events are collected at each clinic visit. Laboratory values and other safety assessment values considered clinically significant by the investigator and meet the definition of adverse event will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of NIO752 in cerebrospinal fluid (CSF)</measure>
    <time_frame>Pre-dose, Days 57, 85, 170</time_frame>
    <description>Concentration of NIO752 in CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, Ctrough in plasma</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3 4, 5, 6, 24 hours post dose, Days 14, 57, 85 and 170</time_frame>
    <description>Maximum and trough level concentrations of NIO752 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax in blood plasma</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3 4, 5, 6, 24 hours post dose, Days 14, 57, 85 and 170</time_frame>
    <description>Time of Cmax in plasma post-IT injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC-last in blood plasma</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3 4, 5, 6, 24 hours post dose, Days 14, 57, 85 and 170</time_frame>
    <description>Area under curve (AUC) from time zero to the last measurable concentration sampling time (t-last) (mass x time x volume-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC-inf in blood plasma</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3 4, 5, 6, 24 hours post dose, Days 14, 57, 85 and 170</time_frame>
    <description>The AUC from time zero to infinity (mass x time x volume-1)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>NIO752 - Dose A - Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intrathecal injection of Dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo - Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single intrathecal injection of artificial cerebrospinal fluid (CSF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIO752 Dose B - Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intrathecal injection of Dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo - Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single intrathecal injection of artificial cerebrospinal fluid (CSF)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIO752</intervention_name>
    <description>A single intrathecal (cerebrospinal) injection of NIO752 of Dose A</description>
    <arm_group_label>NIO752 - Dose A - Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIO752</intervention_name>
    <description>A single intrathecal (cerebrospinal) injection of NIO752 at dose B</description>
    <arm_group_label>NIO752 Dose B - Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>A single intrathecal injection of matching placebo (artificial cerebrospinal fluid)</description>
    <arm_group_label>Matching placebo - Cohort 1</arm_group_label>
    <arm_group_label>Matching placebo - Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Between 30 to 74 years old (both inclusive) at the time of informed consent.&#xD;
&#xD;
          -  A diagnosis of mild Alzheimer's Disease (AD) or mild cognitive impairment (MCI) due to&#xD;
             AD at screening with at least a 6-month decline in cognitive function prior to&#xD;
             screening documented in the medical record. Both participants with sporadic AD as well&#xD;
             as Amyloid Precursor Protein (APP), Presenilin-1 (PSEN1) or Presenilin-2 (PSEN2)&#xD;
             mutation carriers are eligible.&#xD;
&#xD;
          -  Participants must have a diagnosis of MCI due to AD or mild AD at screening as defined&#xD;
             by a Clinical Dementia Rating Scale (CDR) Global Score of 0.5 or 1 and a Memory Score&#xD;
             ≥ 0.5.&#xD;
&#xD;
          -  A history of CSF biomarkers supporting the diagnosis of AD obtained at any time prior&#xD;
             to screening, including CSF amyloid (Aβ42 and/or Aβ42/40 ratio) and tau species (total&#xD;
             tau and/or phosphorylated tau).&#xD;
&#xD;
          -  Participant has a reliable study partner or caregiver (e.g., spouse, sibling, close&#xD;
             friend, adult child) who, is at least 18 years old.&#xD;
&#xD;
          -  Participant resides in a proximity to the study site to allow a timely unscheduled&#xD;
             visit in the study site, if necessary.&#xD;
&#xD;
          -  Participant is able to undergo lumbar puncture (LP), CSF collections, and blood draws,&#xD;
             tolerate brain MRI, and able to participate and tolerate all study procedures at study&#xD;
             visit.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Participant lives in a skilled nursing facility or dementia care facility.&#xD;
&#xD;
          -  Any previous use of experimental therapy within 180 days or 5 half-lives prior to Day&#xD;
             1, whichever is greater. Previous exposure to anti-tau and anti-β-amyloid antibodies&#xD;
             is allowed if at the time of screening at least 180 days have passed since the last&#xD;
             dose. Previous exposure to amyloid vaccines or tau vaccines meant to treat AD, or&#xD;
             previous treatment with oligonucleotides or with gene therapy at any time frame is not&#xD;
             allowed.&#xD;
&#xD;
          -  Any current or past non-AD neurological conditions.&#xD;
&#xD;
          -  Other medical conditions including but not limited to poorly controlled diabetes&#xD;
             mellitus, unstable angina, myocardial infarction, chronic heart failure, clinical&#xD;
             significant conduction abnormalities, impaired renal or kidney function, which, in the&#xD;
             opinion of the Investigator, would make the participant unsuitable for inclusion or&#xD;
             could interfere with the participation in or completion of the study.&#xD;
&#xD;
          -  Treatment with immunosuppressants, antipsychotics, lithium, neuroleptics, dopaminergic&#xD;
             agonists, L-dopa, or monoamine oxidase inhibitors at the time of screening. Current&#xD;
             use of medications, other than cholinesterase inhibitors and/or memantine, that could&#xD;
             alter cognition, as determined by the Investigator. If the participant is receiving&#xD;
             cholinesterase inhibitors and/or memantine, the dose must have been stable within 12&#xD;
             weeks prior to screening, and must remain stable during the duration of the study.&#xD;
&#xD;
          -  Brain MRI at screening or within 12 months prior to screening showing evidence of&#xD;
             cerebrovascular disease such as acute or sub-acute micro- or macrohemorrhage,&#xD;
             significant signs of major cerebrovascular disease, or any other imaging evidence&#xD;
             that, in the opinion of the Investigator, makes the participant unsuitable for the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose-Alberto Palma, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>July 11, 2022</study_first_submitted>
  <study_first_submitted_qc>July 19, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2022</study_first_posted>
  <last_update_submitted>July 19, 2022</last_update_submitted>
  <last_update_submitted_qc>July 19, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Autosomal dominant Alzheimer disease</keyword>
  <keyword>Early onset Alzheimer disease</keyword>
  <keyword>Familial Alzheimer disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Tauopathies</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <keyword>Neurocognitive Disorders</keyword>
  <keyword>Memory loss</keyword>
  <keyword>Placebo</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

